SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: t.gawarecki who wrote (243)9/22/1998 9:03:00 PM
From: Paul Berliner  Respond to of 307
 
I don't think Baxter would be interested in any work with SYBD - Bax saw trouble with Hemassist and thus acquired Somtagen a few months back strictly to stay in the game - that's where their new direction in this side project of there's will be. They not going to dabble with the pefluberon side.



To: t.gawarecki who wrote (243)9/22/1998 10:18:00 PM
From: Rick Hoffmann  Respond to of 307
 
You bet your ever-lovin' sweet A it was written by a poster. I'm still lurking out here, trying to keep the company from spinning their news too much. If you read the latest annual report, you probably noticed that on of the co-authors, Dr. Clark, is only a consultant on the "research" now. While I was listed as key personnel earlier, I ain't no more.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News